Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to quiet artery inflammation and prevent heart attacks

NCT ID NCT07448038

Disease control Sponsor: Genentech, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Sep 04, 2026 · Updated 5 times

Summary

This study tests a drug called selnoflast in 162 people with atherosclerosis (hardened arteries) who are at high risk for heart attacks or strokes. The goal is to see if selnoflast can reduce inflammation inside the arteries, measured by a special PET scan, compared to a placebo. All participants continue their standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
selnoflast
What this could lead to
If it works, this could point toward a new way to lower inflammation in arteries and reduce the risk of heart attacks or strokes in people with atherosclerosis.
What could go wrong
This is an early Phase 2 trial with only 162 participants, so results may not apply to everyone. The drug may not reduce inflammation enough or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 162 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed evidence of atherosclerosis * Left or right carotid TBR ≥ 1.8 or aorta TBR ≥ 2.0 on centrally-assessed 18F-fluorodeoxyglucose-Positron Emission Tomography (18F-FDG-PET) scan * Stable treatment of atherosclerosis through the use of SOC medications or revascularization * QT interval corrected through use of Fridericia's formula (QTcF) of ≤ 450 milliseconds (ms) in men and ≤ 470 ms in women by a single 12-lead electrocardiogram (ECG) recording Exclusion Criteria: * Individuals with Class III and IV heart failure * Uncontrolled cardiac arrhythmia * Uncontrolled hypertension * Suspected or known immunocompromised state * Planned procedure or surgery during the study and any major surgery within 90 days prior to screening Visit 1 * History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer * Positive test results for hepatitis B (HBV) infection at screening * Positive hepatitis C virus (HCV) antibody test at screening * Positive human immunodeficiency virus (HIV) test at screening * Estimated glomerular filtration rate \<50 mL/min/1.73 m² as calculated through use of the Chronic Kidney Disease Epidemiology Collaboration equation, at the time of screening. * Treatment with any live vaccine within 28 days prior to the first dose of study drug until the end of the study * Treatment with other non-live vaccines within 14 days prior to the first dose of study drug until the end of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    24 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ahmed Arif Medical Research Center (AA MRC LLC )

    RECRUITING

    Flint, Michigan, 48504, United States

  • Alliance Clinical West Hills (Focus Clinical Research)

    RECRUITING

    West Hills, California, 91307, United States

  • Amnova Clinical Research

    RECRUITING

    Irvine, California, 92604, United States

  • Asha Clinical Research-Munster,Llc

    RECRUITING

    Hammond, Indiana, 46324, United States

  • Cardio Health Clinical Trials

    RECRUITING

    Hamilton, Ontario, L8W 3K5, Canada

  • Cardiovascular Research Foundation of Southern California

    RECRUITING

    Beverly Hills, California, 90210, United States

  • Cardiovascular Specialists of Willowbrook

    RECRUITING

    Houston, Texas, 77070, United States

  • DiGiovanna Inst for Med Ed&Res

    RECRUITING

    North Massapequa, New York, 11758-1802, United States

  • East Texas Cardiology PA

    RECRUITING

    Houston, Texas, 77002, United States

  • Eastside Research Associates, LLC dba Era Health Research

    RECRUITING

    Redmond, Washington, 98036, United States

  • Inpatient Research Clinic (Las Palmas Medical Research Center)

    RECRUITING

    Miami Lakes, Florida, 33014, United States

  • National Heart Institute

    RECRUITING

    Beverly Hills, California, 90211, United States

  • NorthBay Clinical Research

    RECRUITING

    Santa Rosa, California, 95405, United States

  • Preferred Primary Care Physicians, Inc

    RECRUITING

    Pittsburgh, Pennsylvania, 15243, United States

  • Profound Research LLC at Cardiology and Vascular Associates - CAVA

    RECRUITING

    Bloomfield Hills, Michigan, 48304, United States

  • Profound Research LLC at Millenium Cardiology

    RECRUITING

    Farmington Hills, Michigan, 48334, United States

  • Southwest Family Medicine Associates

    RECRUITING

    Dallas, Texas, 75235, United States

  • UNC Heart & Vascular

    RECRUITING

    Chapel Hill, North Carolina, 27599-7075, United States

  • UT Health San Antonio

    RECRUITING

    San Antonio, Texas, 78229, United States

  • University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 69198-4130, United States

  • Vanderbilt University School of Medicine (VUSM) - Vanderbilt Translational and Clinical Cardiovascular Research Center (VTRACC)

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Washington University, School of Medicine

    RECRUITING

    St Louis, Missouri, 63110, United States

  • Yale University School of Medicine Yale-New Haven Hospital (YNHH) - Smilow Cancer Hospital

    RECRUITING

    New Haven, Connecticut, 06520-8040, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.